Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Study limitation reported by the research below: “Disability progression data were not reported as a primary outcome, so the long-term impact on irreversible disability accumulation remains unclear.”